Gαs and Gαq/11 protein coupling bias of two AVPR2 mutants (R68W and V162A) that cause nephrogenic diabetes insipidus

References

• Schoneberg T, Liebscher I. Mutations in G protein-coupled receptors: mechanisms, pathophysiology and potential therapeutic approaches. Pharmacol Rev. 2021;73(1):89–119.
   PubMed Web of Science ®Google Scholar
• Makita N, Manaka K, Sato J, et al. V2 vasopressin receptor mutations. Vitam Horm. 2020;113:79–99.
   PubMed Web of Science ®Google Scholar
• Gurevich VV, Gurevich EV. Molecular mechanisms of GPCR signaling: a structural perspective. Int J Mol Sci. 2017;18(12):2519.
   PubMed Web of Science ®Google Scholar
• Knoers NV, Deen PM. Molecular and cellular defects in nephrogenic diabetes insipidus. Pediatr Nephrol. 2001;16(12):1146–1152.
   PubMed Web of Science ®Google Scholar
• Morello JP, Bichet DG. Nephrogenic diabetes insipidus. Annu Rev Physiol. 2001;63(1):607–630.
   PubMedGoogle Scholar
• Bichet DG, Birnbaumer M, Lonergan M, et al. Nature and recurrence of AVPR2 mutations in X-linked nephrogenic diabetes insipidus. Am J Hum Genet. 1994;55(2):278–286.
   PubMed Web of Science ®Google Scholar
• Yang LK, Hou ZS, Tao YX. Biased signaling in naturally occurring mutations of G protein-coupled receptors associated with diverse human diseases. Biochim Biophys Acta Mol Basis Dis. 2021;1867(1):165973.
   PubMed Web of Science ®Google Scholar
• Lykke K, Assentoft M, Fenton RA, et al. Vasopressin receptors V1a and V2 are not osmosensors. Physiol Rep. 2015;3(8):e12519.
   PubMedGoogle Scholar
• Armstrong SP, Seeber RM, Ayoub MA, et al. Characterization of three vasopressin receptor 2 variants: an apparent polymorphism (V266A) and two loss-of-function mutations (R181C and M311V). PLOS One. 2013;8(6):e65885.
   PubMed Web of Science ®Google Scholar
• Prosperi F, Suzumoto Y, Marzuillo P, et al. Characterization of five novel vasopressin V2 receptor mutants causing nephrogenic diabetes insipidus reveals a role of tolvaptan for M272R-V2R mutation. Sci Rep. 2020;10(1):16383.
   PubMed Web of Science ®Google Scholar
• Bhardwaj VK, Oakley A, Purohit R. Mechanistic behavior and subtle key events during DNA clamp opening and closing in T4 bacteriophage. Int J Biol Macromol. 2022;208:11–19.
   PubMed Web of Science ®Google Scholar
• Bhardwaj VK, Purohit R. A lesson for the maestro of the replication fork: targeting the protein-binding interface of proliferating cell nuclear antigen for anticancer therapy. J Cell Biochem. 2022;123(6):1091–1102.
   PubMed Web of Science ®Google Scholar
• Kumar S, Bhardwaj VK, Singh R, et al. Identification of acridinedione scaffolds as potential inhibitor of DENV-2 C protein: an in silico strategy to combat dengue. J Cell Biochem. 2022;123(5):935–946.
   PubMed Web of Science ®Google Scholar
• Singh R, Bhardwaj VK, Das P, et al. Identification of 11β-HSD1 inhibitors through enhanced sampling methods. Chem Commun. 2022;58(32):5005–5008.
   PubMed Web of Science ®Google Scholar
• Singh R, Bhardwaj VK, Purohit R. Computational targeting of allosteric site of MEK1 by quinoline-based molecules. Cell Biochem Funct. 2022:1–10.
   Web of Science ®Google Scholar
• Duzenli D, Saglar E, Deniz F, et al. Mutations in the AVPR2, AVP-NPII, and AQP2 genes in Turkish patients with diabetes insipidus. Endocrine. 2012;42(3):664–669.
   PubMed Web of Science ®Google Scholar
• Erdem B, Schulz A, Saglar E, et al. Functional characterization of AVPR2 mutants found in Turkish patients with nephrogenic diabetes insipidus. Endocr Connect. 2018;7(1):56–64.
   PubMed Web of Science ®Google Scholar
• Erdem Tuncdemir B, Mergen H, Saglar Ozer E. Evaluation of pharmacochaperone-mediated rescue of mutant V2 receptor proteins. Eur J Pharmacol. 2019;865:172803.
   PubMed Web of Science ®Google Scholar
• Boselt I, Tramma D, Kalamitsou S, et al. Functional characterization of novel loss-of-function mutations in the vasopressin type 2 receptor gene causing nephrogenic diabetes insipidus. Nephrol Dial Transplant. 2012;27(4):1521–1528.
   PubMed Web of Science ®Google Scholar
• Morello JP, Petaja-Repo UE, Bichet DG, et al. Pharmacological chaperones: a new twist on receptor folding. Trends Pharmacol Sci. 2000;21(12):466–469.
   PubMed Web of Science ®Google Scholar
• Pastrian MB, Guzman F, Garona J, et al. Structure-activity relationship of 1-desamino-8-D-arginine vasopressin as an antiproliferative agent on human vasopressin V2 receptor-expressing cancer cells. Mol Med Rep. 2014;9(6):2568–2572.
   PubMed Web of Science ®Google Scholar
• North WG. Gene regulation of vasopressin and vasopressin receptors in cancer. Exp Physiol. 2000;85(s1):27S–40S.
   PubMedGoogle Scholar
• Liu H, Gruber CW, Alewood PF, et al. The oxytocin receptor signalling system and breast cancer: a critical review. Oncogene. 2020;39(37):5917–5932.
   PubMed Web of Science ®Google Scholar
• Garona J, Pifano M, Orlando UD, et al. The novel desmopressin analogue [V4Q5]dDAVP inhibits angiogenesis, tumour growth and metastases in vasopressin type 2 receptor-expressing breast cancer models. Int J Oncol. 2015;46(6):2335–2345.
   PubMed Web of Science ®Google Scholar
• Zhao N, Peacock SO, Lo CH, et al. Arginine vasopressin receptor 1a is a therapeutic target for castration-resistant prostate cancer. Sci Transl Med. 2019;11(498):eaaw4636.
   PubMed Web of Science ®Google Scholar
• Ma Q, Cao Z, Li H, et al. Two naturally occurring mutations of human GPR103 define distinct G protein selection bias. Biochim Biophys Acta Mol Cell Res. 2021;1868(7):119046.
   PubMed Web of Science ®Google Scholar
• Spanakis E, Milord E, Gragnoli C. AVPR2 variants and mutations in nephrogenic diabetes insipidus: review and missense mutation significance. J Cell Physiol. 2008;217(3):605–617.
   PubMed Web of Science ®Google Scholar
• Fujiwara TM, Bichet DG. Molecular biology of hereditary diabetes insipidus. J Am Soc Nephrol. 2005;16(10):2836–2846.
   PubMed Web of Science ®Google Scholar
• Feldman BJ, Rosenthal SM, Vargas GA, et al. Nephrogenic syndrome of inappropriate antidiuresis. N Engl J Med. 2005;352(18):1884–1890.
   PubMed Web of Science ®Google Scholar
• Janovick JA, Spicer TP, Bannister TD, et al. Pharmacoperone rescue of vasopressin 2 receptor mutants reveals unexpected constitutive activity and coupling bias. PLOS One. 2017;12(8):e0181830.
   PubMed Web of Science ®Google Scholar
• Charest PG, Bouvier M. Palmitoylation of the V2 vasopressin receptor carboxyl tail enhances beta-arrestin recruitment leading to efficient receptor endocytosis and ERK1/2 activation. J Biol Chem. 2003;278(42):41541–41551.
   PubMed Web of Science ®Google Scholar
• Boselt I, Rompler H, Hermsdorf T, et al. Involvement of the V2 vasopressin receptor in adaptation to limited water supply. PLOS One. 2009;4(5):e5573.
   PubMed Web of Science ®Google Scholar
• Tao YX, Conn PM. Pharmacoperones as novel therapeutics for diverse protein conformational diseases. Physiol Rev. 2018;98(2):697–725.
   PubMed Web of Science ®Google Scholar
• Selvaraj S, Rodrigues D, Krishnamoorthy N, et al. Genetic and functional characterization of a novel AVPR2 missense mutation in a woman with X-Linked recessive nephrogenic diabetes insipidus. J Pers Med. 2022;12(1).
   PubMed Web of Science ®Google Scholar
• Tao YX. Molecular chaperones and G protein-coupled receptor maturation and pharmacology. Mol Cell Endocrinol. 2020; Jul 1511:110862.
   PubMed Web of Science ®Google Scholar
• Wang L, Guo W, Fang C, et al. Functional characterization of a loss-of-function mutant I324M of arginine vasopressin receptor 2 in X-linked nephrogenic diabetes insipidus. Sci Rep. 2021;11(1):11057.
   PubMed Web of Science ®Google Scholar
• Seyedabadi M, Ghahremani MH, Albert PR. Biased signaling of G protein coupled receptors (GPCRs): molecular determinants of GPCR/transducer selectivity and therapeutic potential. Pharmacol Ther. 2019;200:148–178.
   PubMed Web of Science ®Google Scholar
• Gurevich VV, Gurevich EV. Biased GPCR signaling: possible mechanisms and inherent limitations. Pharmacol Ther. 2020;211:107540.
   PubMed Web of Science ®Google Scholar
• Wootten D, Christopoulos A, Marti-Solano M, et al. Mechanisms of signalling and biased agonism in G protein-coupled receptors. Nat Rev Mol Cell Biol. 2018;19(10):638–653.
   PubMed Web of Science ®Google Scholar
• Nagi K, Onaran HO. Biased agonism at G protein-coupled receptors. Cell Signal. 2021;83:109981.
   PubMed Web of Science ®Google Scholar
• Franco R, Aguinaga D, Jimenez J, et al. Biased receptor functionality versus biased agonism in G-protein-coupled receptors. Biomol Concepts. 2018;9(1):143–154.
   PubMedGoogle Scholar
• Barak LS, Oakley RH, Laporte SA, et al. Constitutive arrestin-mediated desensitization of a human vasopressin receptor mutant associated with nephrogenic diabetes insipidus. Proc Natl Acad Sci USA. 2001;98(1):93–98.
   PubMed Web of Science ®Google Scholar
• Rodrigues AR, Almeida H, Gouveia AM. Intracellular signaling mechanisms of the melanocortin receptors: current state of the art. Cell Mol Life Sci. 2015;72(7):1331–1345.
   PubMed Web of Science ®Google Scholar
• Yang F, Huang H, Tao YX. Biased signaling in naturally occurring mutations in human melanocortin-3 receptor gene. Int J Biol Sci. 2015;11(4):423–433.
   PubMed Web of Science ®Google Scholar